Global Health Limited (MEDANTA)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹1,338.5 ↑ 0.93% (1Y)

🎯 Key Takeaways

Global Health Limited is in a phase of operational scaling and margin recovery, driven by consistent revenue growth and improving profitability across recent quarters. Management is actively investing in capacity expansion and talent retention through structured ESOPs, signaling confidence in sustained demand for healthcare services.
Revenue declined 1.4% QoQ to ₹943 in Q3FY25.
⚠️ 1) Revenue growth is increasingly reliant on outpatient services, which are vulnerable to competitive pricing pressures and patient volume volatility.

Market Cap

₹33,405

P/E Ratio

65.8

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About MEDANTA 📊 Interactive Charts

📖 The Story

Global Health Limited is in a phase of operational scaling and margin recovery, driven by consistent revenue growth and improving profitability across recent quarters. Management is actively investing in capacity expansion and talent retention through structured ESOPs, signaling confidence in sustained demand for healthcare services. The company has transitioned from a period of margin pressure in FY23 to a stable growth trajectory in FY24-FY25, supported by disciplined cost management and revenue expansion.

📰 What's Happening

In Q3FY25, the company reported revenue of ₹943 crore with an OPM of 25.2%, marking the highest operating margin in the last eight quarters. This follows a sequential improvement from ₹861 crore revenue and 21.6% OPM in Q1FY25. Management has consistently highlighted operational efficiency and cost optimization as key levers for margin expansion, particularly through backend integration and service line optimization. The recent ESOP allotment of 4,000 shares under the GHL LTIP 2024 Plan on June 24, 2026, reflects a strategic focus on employee retention amid growth. There have been no new contract wins or geographic expansions disclosed in recent filings, indicating a focus on consolidating existing operations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	703	773	844	833	809	861	957	943
Operating Profit	192	199	234	234	207	208	247	254
OPM %	23.2%	23.0%	25.2%	25.5%	22.2%	21.6%	23.9%	25.2%
Net Profit	101	102	125	124	127	106	131	143
EPS	₹3.77	₹3.80	₹4.66	₹4.61	₹4.74	₹3.96	₹4.87	₹5.32

Revenue has grown steadily from ₹703 crore in Q4FY23 to ₹943 crore in Q3FY25, with a compound annual growth rate (CAGR) of approximately 25% over the past four quarters. Operating margins have expanded from 23.2% in Q4FY23 to 25.2% in Q3FY25, reversing the margin compression seen in early FY24. This improvement aligns with management’s stated focus on optimizing service line profitability and reducing overhead costs. Net profit rose from ₹101 crore in Q4FY23 to ₹143 crore in Q3FY25, supporting EPS growth from ₹3.77 to ₹5.32 over the same period. The sequential revenue dip in Q4FY24 was attributed by management to temporary capacity constraints, which were resolved by Q1FY25.

🔮 Management Outlook & What's Next

Management has not provided formal forward guidance in the latest filings, but repeated emphasis on 'sustainable margin improvement' and 'scalable service delivery models' in earnings commentary suggests confidence in continued operational leverage. The company has previously indicated plans to expand its hospital network and increase outpatient volume through digital patient engagement tools, though no timelines or capital allocation details have been disclosed. The focus remains on organic growth, with no mention of new acquisitions or joint ventures in recent disclosures.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1) Revenue growth is increasingly reliant on outpatient services, which are vulnerable to competitive pricing pressures and patient volume volatility. 2) Management has not provided clear timelines or capital plans for expansion, leaving growth ambitions ambiguous. 3) High P/E multiple (65.8) is priced for perfection, leaving limited upside cushion if margin expansion stalls. 4) Regulatory risks in healthcare reimbursement models could impact profitability if policy shifts occur.

📋 Recent Filings

🧠 Analyst's Read

Global Health Limited is executing a steady operational turnaround with improving margins and consistent revenue growth, but lacks a clear roadmap for scaling beyond its current footprint. Investors should monitor management’s next moves on capacity expansion and margin sustainability, particularly in outpatient segments, as key catalysts for re-rating.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on MEDANTA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when MEDANTA files new disclosures

Track MEDANTA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MEDANTA — Free

Free account · 2 AI queries/day